SCOR acknowledges the arbitration award confirming the validity of the retrocession treaties entered into with Covéa in June 2021

SCOR has received an arbitration tribunal award on June 25, 2026 confirming the validity of retrocession treaties with Covéa from June 2021 involving the transfer of 30% of SCOR's Life & Health portfolio. The tribunal awarded Covéa USD 488.3 million in compensation. After provisions, the impact on SCOR's net results at Q2 2026 will be approximately EUR 50 million with no negative impact on solvency ratio or liquidity.